Avalo CMO exercises options and sells 1,450 shares
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported an exercise-and-sell transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported an exercise-and-sell transaction in company stock. On June 23, 2026, Mittie exercised options to acquire 1,450 shares of Common Stock at $8.04 per share and sold 1,450 shares at $18.00 per share in an open-market sale. Following these transactions, Mittie directly holds 51,776 Common shares and 116,871 stock options. The filing notes that these trades were made under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were pre-scheduled rather than timed discretionarily.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,450 shares ($14K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Doyle Mittie
Role
Chief Medical Officer
Sold
1,450 shs ($26K)
Approx. gross sale proceeds
$26K
Approx. exercise cost
$12K
Approx. pre-tax spread
$14K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 1,450 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,450 | $8.04 | $12K |
| Sale | Common Stock | 1,450 | $18.00 | $26K |
Holdings After Transaction:
Stock Option (Right to Buy) — 116,871 contracts (Direct);
Common Stock — 51,776 shares (Direct)
Footnotes (2)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Shares sold: 1,450 shares
Sale price: $18.00 per share
Options exercised: 1,450 shares
+5 more
8 metrics
Shares sold
1,450 shares
Common Stock sold on June 23, 2026 at $18.00
Sale price
$18.00 per share
Open-market sale of 1,450 Common Stock shares
Options exercised
1,450 shares
Common Stock acquired via option exercise on June 23, 2026
Exercise price
$8.04 per share
Conversion price for exercised stock option
Shares held after
51,776 shares
Direct Common Stock holdings following transactions
Options remaining
116,871 options
Direct stock option holdings after the reported exercise
10b5-1 plan adoption date
November 13, 2025
Date Doyle Mittie adopted the trading plan governing these trades
Option expiration
January 28, 2035
Expiration date for the exercised stock option grant
Key Terms
Rule 10b5-1 trading plan, stock option (right to buy), open-market sale, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock option (right to buy) financial
"Stock Option (Right to Buy) with 1,450 underlying Common Stock shares..."
open-market sale financial
"transaction_action: open-market sale for 1,450 shares of Common Stock..."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security..."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Common Stock financial
"security_title: Common Stock involved in sale and option exercise..."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Avalo Therapeutics (AVTX) report for Doyle Mittie?
Avalo Therapeutics reported that Chief Medical Officer Doyle Mittie exercised options for 1,450 shares and sold 1,450 Common Stock shares on June 23, 2026. The activity reflects an exercise-and-sell pattern rather than a pure open-market purchase or sale.
Were Doyle Mittie’s Avalo Therapeutics (AVTX) trades made under a Rule 10b5-1 plan?
Yes. The Form 4 footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Such plans pre-schedule trades, reducing the significance of timing as a signal of management’s short-term view.
What type of derivative security did Doyle Mittie exercise at Avalo Therapeutics (AVTX)?
The filing shows an exercise of a stock option (right to buy) for 1,450 underlying Common Stock shares at a $8.04 conversion price. The option expires on January 28, 2035, and remains part of a larger option position after this partial exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
